Shots:
The company presented 2yrs. results from the P-III (LIBERTY-CD) & (LIBERTY-UC) trial evaluating the superiority in safety & efficacy of CT-P13 (SC) vs Remicade in patients (n=180 & 237) with moderately to severely active CD & UC
In the trials, 85.6% & 87% of patients completed the extension phase with clinical remission, clinical response,…
